Unknown

Dataset Information

0

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.


ABSTRACT:

Objective

To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy.

Research design and methods

Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43).

Results

Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P < 0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion.

Conclusions

In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.

SUBMITTER: Alkhalaf A 

PROVIDER: S-EPMC2890365 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3766986 | biostudies-other
| S-EPMC2092425 | biostudies-other
| S-EPMC5629141 | biostudies-literature
2016-07-15 | E-GEOD-76003 | biostudies-arrayexpress
| S-EPMC4077042 | biostudies-other
2016-07-15 | GSE76003 | GEO
2017-02-09 | GSE74988 | GEO
| S-EPMC5947135 | biostudies-other
| S-EPMC7912007 | biostudies-literature
2024-07-10 | MSV000095296 | MassIVE